EU regulators approve Takeda’s Adcetris for sALCL
The decision brings a ‘much needed’ new treatment option to this patient community
Read More
Tag: brentuximab
NICE OKs three new therapies for blood cancer
Cost regulators for the NHS are recommending that three new types of treatment for people with blood cancer are made available on the NHS England and Wales.
Read More
NICE u-turn backs Takeda’s Adcetris for sALCL
Takeda’s Adcetris has now been backed by the National Institute for Health and Care Excellence as an option to treat systemic anaplastic large cell lymphoma (sALCL), a very rare and aggressive cancer of the lymphatic system, on the NHS in England and Wales.
Read More
Final NICE nod for Takeda’s Adcetris in Hodgkin’s lymphoma
Certain patients with Hodgkin’s Lymphoma living in England and Wales can now expect routine access to Takeda’s Adcetris on the NHS after NICE deemed the drug a cost-effective use of resources in some scenarios.
Read More
NICE u-turn recommends some access to Takeda’s Adcetris
It is now looking likely that some patients with relapsed/refractory (R/R) Hodgkin lymphoma will be able to get routine access to Takeda’s Adcetris on the NHS after a major u-turn by cost regulators.
Read More
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
